{"filing":{"accession_number":"0001104659-26-094466","cik":"0001408443","ticker":"MIST","company_name":"Milestone Pharmaceuticals Inc.","form":"8-K","filing_date":"2026-08-12","report_date":"2026-08-12","primary_document":"tm2614433d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1408443/000110465926094466/tm2614433d1_8k.htm"},"events":[{"id":27032,"run_id":24601,"accession_number":"0001104659-26-094466","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Item 2.02 discloses Milestone Pharmaceuticals' second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The filing reports Q2 product revenues of $0.6 million, net loss of $28.6 million ($0.21 per share), cash position of $170.6 million, and operational highlights including CARDAMYST launch progress and Phase 3 trial activation for AFib-RVR. This is a standard earnings release disclosure material to investors assessing the company's financial condition and commercial progress.","company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","filing_date":"2026-08-12","form":"8-K","submitted_at":null,"items":[{"id":28385,"accession_number":"0001104659-26-094466","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Milestone Pharmaceuticals' second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The filing reports Q2 product revenues of $0.6 million, net loss of $28.6 million ($0.21 per share), cash position of $170.6 million, and operational highlights including CARDAMYST launch progress and Phase 3 trial activation for AFib-RVR. This is a standard earnings release disclosure material to investors assessing the company's financial condition and commercial progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:29:37.342572+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":28385,"accession_number":"0001104659-26-094466","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Item 2.02 discloses Milestone Pharmaceuticals' second quarter 2026 financial results via a press release furnished as Exhibit 99.1. The filing reports Q2 product revenues of $0.6 million, net loss of $28.6 million ($0.21 per share), cash position of $170.6 million, and operational highlights including CARDAMYST launch progress and Phase 3 trial activation for AFib-RVR. This is a standard earnings release disclosure material to investors assessing the company's financial condition and commercial progress.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-12T11:29:37.342572+00:00","company_name":"Milestone Pharmaceuticals Inc.","ticker":"MIST","filing_date":"2026-08-12"}]}